Freedom to Operate Analysis for MedTech Startups: A Practical FTO Search Guide

2026-09-24 · Caduvo Team

What a freedom to operate analysis is, when your device startup needs one, and how FTO fits alongside patentability and regulatory planning. Practical steps for founders.

You’ve locked down a design that solves a real clinical problem. Your regulatory lead is mapping out a 510(k) submission. Then a patent attorney mentions you might be walking into a competitor’s patent thicket. If you haven’t run a freedom to operate analysis, that risk could have been sitting unnoticed for months.

What Freedom to Operate Means (vs. Patentability)

A freedom to operate analysis answers one question: can you commercialize your device without infringing enforceable patent claims owned by another party? It has nothing to do with whether your invention is new enough to patent. Those are two separate legal tests.

Patentability asks whether your invention meets novelty and non-obviousness standards, and it leads to you owning a patent. An FTO analysis checks whether anyone else owns an in-force patent that would block you from making, using, or selling your device in a specific country. You can hold a dozen patents on your device and still infringe someone else’s earlier patent. That distinction trips up a lot of medtech startup teams.

Example: you develop a novel biodegradable scaffold for a vascular stent. You file your own patent on the scaffold material. But a competitor holds a broad patent on the mechanical deployment mechanism inside the delivery catheter — a component you use off the shelf. Your scaffold patent doesn’t give you the right to use that mechanism if it’s covered by someone else’s claim. An FTO analysis surfaces that conflict.

What an FTO Search Covers (It’s About Claims, Not Abstracts)

A freedom to operate search isn’t a quick keyword scan. It’s a claim-by-claim review of in-force patents and published patent applications in every jurisdiction where you intend to sell. The claim language defines the legal metes and bounds, not the abstract, not the title, and not the product description in a marketing brochure. Two patents can sound identical in an abstract but have claims that cover entirely different territory.

A proper search includes:

Active and expired U.S. utility and design patents (expired patents are free to use).
Pending published applications — these may issue later and become blocking.
Foreign patents in target markets (EP, JP, etc.) if you plan to sell there.
Sometimes patent families to assess global coverage.

Initial database screening (USPTO, Espacenet, Google Patents) helps map the landscape, but a formal opinion comes from a patent attorney who reads the claims and applies them to your device’s technical specifications. Attorneys also check for continuations, divisionals, and reissues that might broaden scope retroactively.

When to Run an FTO Analysis in the Product Lifecycle

You don’t run a full-blown FTO at the napkin-sketch phase. You also don’t wait until the week before launch. The cost of redesigning a locked-down device skyrockets the later you discover a blocking patent.

Here’s the cadence that most medtech startup teams find workable:

Concept stage: Do a lightweight patent landscape search yourself to flag obvious clusters. Rule out designs that are clearly surrounded. No need for a paid opinion yet.
Design freeze / device specification lock: This is the first time you can do a meaningful freedom to operate analysis. The design is stable enough to compare against patent claims. If a conflict emerges, you still have time to design around it without blowing your development budget.
Pre-510(k) or pre-regulatory submission: If your pathway relies on a predicate device, the FTO analysis should examine whether that predicate or its family of patents still casts a shadow. Choosing a predicate that isn’t densely patent-encumbered is as much an IP decision as a regulatory one. This is also when investors ask for an FTO opinion.
Before manufacturing scale-up: Tooling and supply-chain commitments make redesign expensive. Run a confirmation search to catch any newly issued patents.
Pre-launch: A final check, especially in jurisdictions where patent prosecution moves fast.

Tools like Caduvo can layer patent landscape data onto FDA and reimbursement intelligence, which helps you catch conflicts earlier when your regulatory strategy and FTO picture are influencing each other.

What an FTO Analysis Costs and How to Budget

There’s no fixed price, but here are practical ranges for a U.S.-focused medtech startup:

A limited search with a patentability-style screen but focused on in-force claims for a single embodiment: $5,000–$8,000.
A formal written opinion from a patent attorney covering the U.S. and one or two other major markets: $12,000–$20,000.
A complex multi-component system (e.g., a robotic surgery platform) searched across multiple jurisdictions: $30,000 and north.

You can reduce costs by doing the initial patent landscape yourself and giving the attorney a curated list of the 10–15 most relevant patents. But don’t rely solely on an engineer’s keyword search. A non-infringement opinion from a patent attorney has legal weight if you ever face a willful infringement claim. Some firms offer fixed-fee FTO packages for common device categories — worth asking about.

Design-Around Strategies When You Hit a Blocking Patent

If an FTO analysis turns up a patent claim that reads on your device, you have options that don’t involve folding the company:

Narrow the feature: Modify the accused component so it falls outside the literal scope of the claim. This works best when the patent is narrow and you can substitute a functionally equivalent mechanism that isn’t covered.
License the patent: Approach the patent holder before you launch. Early negotiation often yields more favorable terms. If the patent owner is a non-practicing entity, they may accept a royalty that fits your margin model.
Challenge validity: If you have strong prior art, you can file for inter partes review (IPR) at the PTAB to try to kill the claims before they can be asserted against you. This is expensive and uncertain, but it sometimes reshapes the landscape.
Wait it out: If the blocking patent expires in 18 months, you might time your launch accordingly. For a medtech startup, that wait may be impractical, but it’s a data point.
Carve out geographies: The patent may only be in force in certain countries. You might launch first in markets where it’s absent.

Every design-around creates a new device variant, so loop your regulatory team in immediately. Changing a component could trigger a new 510(k) or require additional testing. The FTO analysis and the regulatory pathway are entangled.

Actionable Takeaways

Run a preliminary patent landscape at the concept stage; don’t pay for a formal opinion until design freeze.
A freedom to operate search requires comparing your final device specification to the actual claims of in-force patents — not abstracts or titles.
Budget $10,000–$25,000 for a typical medtech startup’s first FTO analysis covering the U.S. market.
Combine the FTO timeline with your FDA strategy. If you’re relying on a predicate device, check its patent landscape early.
When a blocking patent surfaces, design-around, license, challenge, or adjust your market entry order — but don’t ignore it.